Abstract: OBJECTIVE To establish the drug use evaluation(DUE) standard of rivaroxaban and provide a reference for the rationally clinical application of rivaroxaban. METHODS Based on the rivaroxaban drug label, related guidelines and literature, combined with clinical expert consultation results, DUE standard from three aspects(indications, medications and medication results) was established. A retrospective survey was conducted to evaluate the inpatients using rivaroxaban from January 2018 to June 2019 in Zhangzhou Affiliated Hospital of Fujian Medical University. RESULTS A total of 591 patients were included, with a medication reasonable rate of 60.41%. The irrational use of drugs was mainly in the low dose(27.75%), off-label medication(11.50%) and drug interactions(9.64%). CONCLUSION The rivaroxaban DUE standard established is scientific, practical and feasible. It can be further optimized in contraindications and use of proton pump inhibitors to prevent rivaroxaban-related gastric mucosal damage and the management of off-label medication.